Hepatitis b breakthrough? new drug AHB-137 shows promise in Long-Term Follow-Up

NCT ID NCT07146100

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study checks if people with chronic hepatitis B who got better with the drug AHB-137 stay virus-free over time. About 200 adults who already responded to AHB-137 will be followed for years. The goal is to see if the virus stays undetectable and if liver health improves without needing more treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • AusperBio Investigational Site

    RECRUITING

    Guangzhou, Guangdong, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • AusperBio Investigational Site

    RECRUITING

    Changchun, Jilin, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••